Statistics of Rimonabant improves cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA(1c)>= 8%) on monotherapy with metformin or sulfonylureas

Created with Highcharts 9.2.2Number of downloadsChart context menuNumber of downloadsGenerated via ORBi - 23/05/2025
Loading...
Created with Highcharts 9.2.2Number of downloadsChart context menuNumber of downloads by countryGenerated via ORBi - 23/05/2025
Loading...
Created with Highcharts 9.2.2Number of viewsChart context menuNumber of viewsGenerated via ORBi - 23/05/2025
Loading...
Created with Highcharts 9.2.2Number of viewsChart context menuNumber of views by countryGenerated via ORBi - 23/05/2025
Loading...
Created with Highcharts 9.2.2Chart context menuOrigin of ORBi's visitorsGenerated via ORBi - 23/05/2025
Loading...
Contact ORBi